Welcome to our home for news – the latest headlines, all in one place. Click through to view a selection of our media coverage, industry news, videos and more.
#Botanix is pleased to share that an article featuring sofpironium topical gel, 12.45% (Sofdra) appears in the July 2025 issue of the peer-reviewed Journal of the American Academy of Dermatology (JAAD). The article presents pooled efficacy and safety results from 2 phase 3 randomized, controlled, double-blind studies that formed the basis for US Food and Drug Administration approval of Sofdra.
https://botanixpharma.com/wp-content/uploads/1184131682_SML.jpg10371843Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2025-06-30 00:39:392025-06-30 00:39:39Sofpironium topical gel (Sofdra) featured in JAAD
Botanix Pharmaceuticals has been featured in Dr Boreham’s Crucible, a column focusing on the Australian biotechnology and healthcare sectors. The interview with CEO, Dr Howie McKibbon includes in-depth look at Botanix and its fulfilment platform, commercialization strategies, company history, and an update on the launch of Sofdra™ (sofpironium) gel, 12.45% in the US.
Botanix has entered into documentation with Kreos Capital for a loan facility of up to US$30 million (~A$48 million).
Kreos Capital is a leading provider of growth and venture debt financing to companies in the technology and healthcare industries. The new debt facility will be available to Botanix for working capital purposes for the commercialisation of Sofdra™, as well as other platform expansion opportunities. H.C. Wainwright & Co. acted as origination, structuring and placement agent for the transaction.
https://botanixpharma.com/wp-content/uploads/BOT-Euroz-Hartleys.png8501600Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2025-05-13 04:15:572025-05-13 04:15:58Euroz Hartleys Research Report | BOT: All Bark No Bite
Botanix CEO Howie McKibbon spoke with Stockhead’s Tylah Tully about Botanix’s elevation to the S&P/ASX 300 index, and the Company’s ambitions to become a global leader in dermatology innovation.
Here’s an excerpt:
“It’s a great honour and validation to join this league and a validation of the work that we’ve done and of our growth as a company. We’ll continue to focus on building Botanix to become the world’s largest and most innovative dermatology company.”
https://botanixpharma.com/wp-content/uploads/Screenshot-2025-03-17-at-9.04.41-am.png6741203Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2025-03-16 22:04:292025-03-16 22:05:42Stockhead | Interview with Howie McKibbon
Botanix CEO Howie McKibbon joined Sharecafe’s Abby Phillips this week to provide an update on the Company’s recent US launch of Sofdra™ and its commercial progress.
Howie shared insights on Botanix’s experienced sales team, momentum in securing contracts with payer organizations covering over 90% of commercially insured lives plus Medicaid, and early results from a digital marketing campaign that’s driving awareness and converting online interest into prescriptions.
https://botanixpharma.com/wp-content/uploads/Unknown-1.png19363450Haley Chartres/wp-content/uploads/botanix-logo.pngHaley Chartres2025-03-16 21:57:582025-03-24 03:01:53Sharecafe | Interview with Howie McKibbon
Sofpironium topical gel (Sofdra) featured in JAAD
/in Featured, Journal Articles, Latest News, News /by Haley Chartres#Botanix is pleased to share that an article featuring sofpironium topical gel, 12.45% (Sofdra) appears in the July 2025 issue of the peer-reviewed Journal of the American Academy of Dermatology (JAAD). The article presents pooled efficacy and safety results from 2 phase 3 randomized, controlled, double-blind studies that formed the basis for US Food and Drug Administration approval of Sofdra.
Click here to read the article.
Dr Boreham’s Crucible features Botanix
/in Featured, Latest News, News /by Haley ChartresBotanix Pharmaceuticals has been featured in Dr Boreham’s Crucible, a column focusing on the Australian biotechnology and healthcare sectors. The interview with CEO, Dr Howie McKibbon includes in-depth look at Botanix and its fulfilment platform, commercialization strategies, company history, and an update on the launch of Sofdra™ (sofpironium) gel, 12.45% in the US.
Click here to read the full report.
Botanix signs debt facility with Kreos Capital
/in ASX Releases, Featured, Latest News /by Haley ChartresBotanix has entered into documentation with Kreos Capital for a loan facility of up to US$30 million (~A$48 million).
Kreos Capital is a leading provider of growth and venture debt financing to companies in the technology and healthcare industries. The new debt facility will be available to Botanix for working capital purposes for the commercialisation of Sofdra™, as well as other platform expansion opportunities. H.C. Wainwright & Co. acted as origination, structuring and placement agent for the transaction.
Click to read the ASX release.
Euroz Hartleys Research Report | BOT: All Bark No Bite
/in Featured, Latest News, News /by Haley ChartresEuroz Hartleys has published a research note on Botanix maintaining a price target of $0.80.
The report addresses President Trump’s recent executive order on drug pricing and concludes it will have “little to no impact” on BOT or Sofdra™.
Click here to read the full report.
Stockhead | Interview with Howie McKibbon
/in Featured, Latest News, News, Videos /by Haley ChartresBotanix CEO Howie McKibbon spoke with Stockhead’s Tylah Tully about Botanix’s elevation to the S&P/ASX 300 index, and the Company’s ambitions to become a global leader in dermatology innovation.
Here’s an excerpt:
“It’s a great honour and validation to join this league and a validation of the work that we’ve done and of our growth as a company. We’ll continue to focus on building Botanix to become the world’s largest and most innovative dermatology company.”
Sharecafe | Interview with Howie McKibbon
/in Featured, Latest News, News /by Haley ChartresBotanix CEO Howie McKibbon joined Sharecafe’s Abby Phillips this week to provide an update on the Company’s recent US launch of Sofdra™ and its commercial progress.
Howie shared insights on Botanix’s experienced sales team, momentum in securing contracts with payer organizations covering over 90% of commercially insured lives plus Medicaid, and early results from a digital marketing campaign that’s driving awareness and converting online interest into prescriptions.